ALK-ABELLO AS DK -50
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more
ALK-ABELLO AS DK -50 (4AJ0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ALK-ABELLO AS DK -50 (4AJ0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ALK-ABELLO AS DK -50 - Net Assets Trend (None–None)
This chart illustrates how ALK-ABELLO AS DK -50's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ALK-ABELLO AS DK -50 (None–None)
The table below shows the annual net assets of ALK-ABELLO AS DK -50 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ALK-ABELLO AS DK -50's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ALK-ABELLO AS DK -50 Competitors by Market Cap
The table below lists competitors of ALK-ABELLO AS DK -50 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MIRION TECHNOL. DL-0001
F:55I0
|
$3.71 Billion |
|
Hims Hers Health Inc
NYSE:HIMS
|
$3.71 Billion |
|
United Community Banks, Inc.
NASDAQ:UCB
|
$3.71 Billion |
|
Mazda Motor Corporation
PINK:MZDAF
|
$3.71 Billion |
|
Anhui Yingliu
SHG:603308
|
$3.71 Billion |
|
GERDAU S.A. PFD
F:GDUB
|
$3.70 Billion |
|
CLICKS GROUP LTD RC-01
F:N1C
|
$3.70 Billion |
|
Dolby Laboratories
NYSE:DLB
|
$3.70 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALK-ABELLO AS DK -50's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ALK-ABELLO AS DK -50's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ALK-ABELLO AS DK -50 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ALK-ABELLO AS DK -50's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $338,657,802
- Average return on equity (ROE) among peers: -66.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALK-ABELLO AS DK -50 (4AJ0) | €- | N/A | N/A | $3.71 Billion |
| 09R (09R) | $-2.13 Million | 0.00% | 0.00x | $10.61 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| Argen-X (1AE) | $4.10 Billion | -7.20% | 0.11x | $38.55 Billion |
| 1S90 (1S90) | $131.51 Million | -49.87% | 1.70x | $52.41 Million |
| Strategic Partners A/S (1TB0) | $19.25 Million | -1.55% | 0.22x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.50 Million |
| Intervacc AB (publ) (2E9) | $162.33 Million | -46.52% | 0.15x | $3.64 Million |
| 2F5 (2F5) | $-1.76 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $8.56 Million |